Newport-based Xanodyne Pharmaceuticals Inc. has sold the global rights of women’s health product Lystedal to Ferring Pharmaceuticals, a privately owned specialty biopharmaceutical group headquartered in Switzerland. The sale is part of Xanodyne’s plan to tighten its focus on the pain management market, where it has a decade-long history with brands such as Darvocet and Roxicodone. The most recent addition to the company’s pain portfolio is Zipsor liquid-filled capsules, a non-steroidal anti-inflammatory drug that was approved by the FDA in June 2009. Financial details of the Xanodyne-Ferring transaction have not been disclosed.
-
Share This!
Newport
June 1, 2010
352 Views
You may also like
Popular Stories
Poll: Beshear most popular Democrat governor again
April 25, 2024
EKU’s Central Ky Regional Airport building $4.5M terminal
April 23, 2024
Lifepoint reports $200M+ economic impact in Cen Ky
April 25, 2024
The Lane Report
- UK researchers study turning solid waste into aviation fuel
- Murray State cybersecurity program recognized
- MSU Vet Tech ranked #1 in Kentucky and13th in the Nation
- UofL receives more than $450M in capital project funding
- Poll: Beshear most popular Democrat governor again
- Lifepoint reports $200M+ economic impact in Cen Ky
- UK Pharmacy dean continuing work with promising anti-malarial drug
- EPC-Columbia adding 21 jobs in Lebanon with $3.6M investment
- Kentucky State University names Grant Stepp athletic director
- UK announces 1st-of-its-kind Estate Whiskey Alliance
Add Comment